If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynectics Regulatory News (SNX)

Share Price Information for Synectics (SNX)

Share Price is delayed by 15 minutes
Get Live Data
200.00    0.00 (0.00%)
Bid:
195.00
Ask:
205.00
Spread: 10.00 (5.128%)
Market Cap: £34.01m
SNX Live PriceLast checked at - London Stock Exchange

Intraday Synectics Share Chart

Directorate Change

6 Jun 2006 07:02

Synexus Clinical Research PLC06 June 2006 Synexus Clinical Research Plc ("the Company") Directorate change Synexus Clinical Research Plc is pleased to announce the appointment of MalcolmHughes (aged 52) as Non-Executive Director with immediate effect. Malcolm is currently Chief Executive of Greenman Group plc ("Greenman"), aprivate industrial company which supplies printer cartridges to European officesupplies distributors from its manufacturing base in Bulgaria. Prior toGreenman, he was Chief Executive of Oasis Healthcare Plc for four years duringwhich Oasis grew from a small regional business to become the leading dentalpractice owner/operator in the UK with turnover of over Β£70m. His previousexperience includes senior management roles at Chloride Group plc, LadbrokeGroup plc and Management Consulting Group plc. Commenting on the appointment, Michael Fort, chief executive of Synexus said : " I am delighted to welcome Malcolm to the Synexus board. He brings with himconsiderable knowledge and expertise, not only within the healthcare industrybut also particular experience of business operations within the emergingeconomies of Eastern Europe where Synexus has established a foothold and fromwhich we aim to expand rapidly. We look forward to benefiting from hiscontribution to the development and implementation of our growth strategy." Malcolm Hughes commented: "I am delighted to be joining Synexus at a time when it is seeking to build onits recent AIM flotation through expansion of its operations in the UK andinternationally. Its unique business model offers a strong proposition to globalpharmaceutical companies as they aim to develop more cost-effective methods oftrialling new drug treatments." Additional Information The following is a complete list of Mr Hughes' directorships as required underSchedule 2(g) of the AIM Rules: Current Previous in last 5 yearsGreenman Group plc Oasis Healthcare PlcGreenman UK Limited Oasis Dental Care LimitedGreenman Europe BV The Dencare Management Group LimitedK2 Supplies Limited Dencare Management LimitedPaprika Services Limited Dencare Financial Services LimitedBetforum UK Limited Dencare Developments Limited Dencare Implant Centres Limited Ora Dental Group Holdings Limited Ora Dental Group Limited Ora EBT Trustee Limited Inhoco 978 Limited Inhoco 979 Limited There is no further information required to be disclosed under Schedule 2(g) ofthe AIM Rules. For further information: Michael Fort, Chief Executive, Synexus Clinical Research PLC 01257 230 723 Zoe Biddick, Biddicks 020 7448 1000 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Jan 20258:40 amRNSHoldings in Company
6th Jan 20258:30 amRNSHoldings in Company
9th Dec 20241:30 pmRNSHoldings in Company
9th Dec 20247:00 amRNSTrading Update
5th Dec 20247:00 amRNS$2.7 million Contract Awards
27th Nov 20247:00 amRNSHolding(s) in Company
25th Nov 20247:00 amRNSContract Awards
18th Nov 20247:00 amRNSAppointment of CEO and Award of Options
4th Nov 20247:00 amRNSContract Awards
3rd Oct 20247:00 amRNSHolding(s) in Company
3rd Oct 20247:00 amRNSHolding(s) in Company
2nd Oct 20247:00 amRNSPDMR dealings
16th Sep 20247:00 amRNSTrading Update
9th Sep 20247:00 amRNSUS$3.2 million contract award
4th Sep 20241:30 pmRNSPDMR Dealings
29th Aug 20247:00 amRNSPassing of Paul Webb, Chief Executive Officer
21st Aug 20247:00 amRNSNotifiable Interest in Shares
1st Aug 20241:45 pmRNSHoldings in Company
9th Jul 20244:40 pmRNSHoldings in Company
9th Jul 20247:00 amRNSHalf-year Report
21st Jun 20247:00 amRNSBoard Appointment
18th Jun 20247:00 amRNSUS$10 million contract win
13th Jun 202410:00 amRNSNotice of Investor Presentation
4th Jun 20247:00 amRNSTrading Update
15th May 20247:00 amRNSDirector/PDMR Dealings
24th Apr 202410:00 amRNSResult of AGM
24th Apr 20247:00 amRNSAGM Statement
17th Apr 20247:00 amRNSContract win with a major UK utility provider
9th Apr 20247:00 amRNSBoard Appointment and Grant of Options
3rd Apr 20247:00 amRNSDirector/PDMR Dealings
26th Mar 20247:00 amRNSDirectors / PDMRs' Interests in Shares
26th Mar 20247:00 amRNSDirector/PDMR Shareholding
19th Mar 20247:00 amRNSPosting of Annual Report & Accounts, Notice of AGM
27th Feb 20247:00 amRNSFinal Results
7th Feb 20247:00 amRNSNotice of Results and Investor Presentation
30th Jan 20247:00 amRNSContract Awards
19th Dec 20233:00 pmRNSHolding(s) in Company
11th Dec 20237:00 amRNSTrading Update
29th Nov 20237:00 amRNSContract Win
15th Nov 20237:00 amRNSInvestor Site Visit
23rd Oct 20237:00 amRNSDirectorate Changes
16th Oct 20237:00 amRNSLatest Release of Synectics’ Synergy Software
11th Oct 20237:00 amRNSDirector/PDMR Dealings
28th Sep 20237:00 amRNSAdditional Contract with West Midlands Police
11th Jul 20237:00 amRNSHalf-year Report
4th Jul 20237:00 amRNSContract Award
3rd Jul 20237:00 amRNSInvestor Presentation re interim results
19th Jun 20237:00 amRNSTrading Update and Notification of Results
11th May 20237:00 amRNSDirector dealings
2nd May 20237:00 amRNSNew Gaming Project in Asia

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.